Prosecution Insights
Last updated: May 29, 2026

Figene LLC

25 pending office actions • 13 art units • 22 examiners • 0 of 25 (0%) have an AI response strategy ready

Portfolio Summary

25
Total Pending OAs
18
Non-Final OAs
7
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 25 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

15
Overdue
0
Due this week
3
Due this month
4
Due in next 60 days
3
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 25 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (15)Due ≤ 30 days (3)Due ≤ 60 days (4)Due later (3)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
16
Medium (64%)
2
Easy (8%)
7
Unknown (28%)

Rejection Statute Mix

BucketCases
§103 only15 (60%)
§112 only2 (8%)
Double-patenting + other1 (4%)
No statute on record7 (28%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

25
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

250 h
Manual time on pending OAs
50 h
Time saved (low, 20%)
88 h
Time saved (mid, 35%)
2.2 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
TRAN, KHOA NHAT 3 35.4% +66.3%
MIANO, JOSEPH PAUL 2 37.9% +63.3%
EBBINGHAUS, BRIANA NOEL 1 57.4% +67.0%
CHEN, CATHERYNE 1 37.4% +18.4%
LEONARD, ARTHUR S 1 50.5% +50.7%
LEVIN, JOEL D 1 52.3% +58.4%
FOX, ALLISON M 1 71.5% +36.1%
BABIC, CHRISTOPHER M 1 60.7% +22.5%
PALENIK, JEFFREY T 1 54.1% +26.7%
OGUNBIYI, OLUWATOSIN A 1 63.3% +42.1%

Interview Candidates (13)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.

App #TitleExaminerDue in
17999588 AUGMENTATION OF FIBROBLAST CELL THERAPY EFFICACY BY MICROBIOME MANIPULATION BABIC, CHRISTOPHER M 142d overdue
17309649 THERAPEUTIC USES OF GENE EDITED FIBROBLASTS TRAN, KHOA NHAT 127d overdue
18040345 REDUCTION OF COVID-19 COAGULOPATHY AND OTHER INFLAMMATION-ASSOCIATED COAGULOPATHIES BY ADMINISTRATION OF FIBROBLASTS MIANO, JOSEPH PAUL 73d overdue
17052859 PAIN-REDUCING EFFECTS OF FIBROBLASTS AND TREATMENT OF PAIN TRAN, KHOA NHAT 73d overdue
17310007 FIBROBLAST REGENERATIVE CELLS TRAN, KHOA NHAT 25d overdue
18486731 GENE THERAPY FOR THE REGENERATION OF CHONDROCYTES OR CARTILAGE TYPE CELLS LEONARD, ARTHUR S 18d overdue
18658989 MEANS AND METHODS OF PREVENTING OR REVERSING AGING EBBINGHAUS, BRIANA NOEL 10d overdue
17905197 GENERATION OF AUTOIMMUNE INHIBITORY T CELLS BY FIBROBLAST MEDIATED EDUCATION MIANO, JOSEPH PAUL 27d

Top Art Units

Art UnitApps
1632 6
1631 5
1633 3
1653 2
1655 1
1615 1
1645 1
1643 1
1627 1
1646 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18658989 MEANS AND METHODS OF PREVENTING OR REVERSING AGING EBBINGHAUS, BRIANA NOEL 1632 §103 Non-Final OA 10d overdue Pending May 09, 2024
18615328 STIMULATION OF ANGIOGENESIS BY FIBROBLAST DERIVED EXOSOMES CHEN, CATHERYNE 1655 DPOther Non-Final OA 70d Pending Mar 25, 2024
18486731 GENE THERAPY FOR THE REGENERATION OF CHONDROCYTES OR CARTILAGE TYPE CELLS LEONARD, ARTHUR S 1631 Other Non-Final OA 18d overdue Pending Oct 13, 2023
18042323 DENTAL AND PERIODONTAL APPLICATION OF FIBROBLASTS LEVIN, JOEL D 1633 §103 Non-Final OA 34d Pending Feb 21, 2023
18040345 REDUCTION OF COVID-19 COAGULOPATHY AND OTHER INFLAMMATION-ASSOCIATED COAGULOPATHIES BY ADMINISTRATION OF FIBROBLASTS MIANO, JOSEPH PAUL 1631 §103 Non-Final OA 73d overdue Pending Feb 02, 2023
17999583 FIBROBLAST THERAPY FOR PREVENTION AND REVERSION OF ANEURYSMS FOX, ALLISON M 1633 Other Non-Final OA 42d Pending Nov 22, 2022
17999588 AUGMENTATION OF FIBROBLAST CELL THERAPY EFFICACY BY MICROBIOME MANIPULATION BABIC, CHRISTOPHER M 1633 §103 Non-Final OA 142d overdue Pending Nov 22, 2022
17997674 REDUCTION OF CYTOKINE STORM AND PATHOLOGICAL INFLAMMATION INCLUDING CAUSED BY CORONAVIRUS USING SPHAGNUM AND EXTRACTS THEREOF PALENIK, JEFFREY T 1615 §103 Final Rejection 72d Pending Nov 01, 2022
17996109 GENE MODIFIED FIBROBLASTS FOR THERAPEUTIC APPLICATIONS OGUNBIYI, OLUWATOSIN A 1645 §103 Final Rejection 56d Pending Oct 13, 2022
17996033 TREATMENT OF ERECTILE DYSFUNCTION BY FIBROBLAST ADMINISTRATION ZHU, JIANJIAN 1631 Other Non-Final OA 54d Pending Oct 12, 2022
17907115 METHODS AND COMPOSITIONS FOR ALLERGY AND ASTHMA TREATMENT USING FIBROBLASTS SCHUBERG, LAURA J 1631 Other Final Rejection 31d overdue Pending Sep 23, 2022
17905197 GENERATION OF AUTOIMMUNE INHIBITORY T CELLS BY FIBROBLAST MEDIATED EDUCATION MIANO, JOSEPH PAUL 1631 Other Non-Final OA 27d Pending Aug 29, 2022
17755834 FIBROBLAST THERAPY FOR INFLAMMATORY BOWEL DISEASE MOSS, NATALIE M 1653 §103 Final Rejection 32d overdue Pending May 10, 2022
17755275 FIBROBLAST-DERIVED UNIVERSAL IMMUNOLOGICAL COMPOSITION BARRON, SEAN C 1653 Other Final Rejection 16d overdue Pending Apr 26, 2022
17755278 INTRATUMORAL ADMINISTRATION OF IMMUNE CELLULAR THERAPEUTICS CHATTIN, AMY MARIE 1643 §103 Final Rejection 72d Pending Apr 26, 2022
17753487 TREATMENT OF TRAUMATIC ENCEPHALOPATHY BY FIBROBLASTS AND THERAPEUTIC ADJUVANTS ROBINSON, MIKHAIL O'DONNEL 1627 §103 Non-Final OA 112d overdue Pending Mar 04, 2022
17595112 FIBROBLAST GENERATED PATIENT-SPECIFIC VACCINES CHASE, CAROL ANN 1646 §103 Non-Final OA 43d overdue Pending Nov 09, 2021
17594730 ENHANCEMENT OF FIBROBLAST THERAPEUTIC ACTIVITY BY T CELL MODULATION HOWARD, ZACHARY C 1674 §112 Non-Final OA 112d overdue Pending Oct 27, 2021
17310051 FIBROBLASTS AND MICROVESICLES THEREOF FOR REDUCTION OF TOXICITY ASSOCIATED WITH CANCER IMMUNOTHERAPY DHAR, MATASHA 1632 Other Non-Final OA 86d overdue Pending Jul 13, 2021
17310007 FIBROBLAST REGENERATIVE CELLS TRAN, KHOA NHAT 1632 §103 Non-Final OA 25d overdue Pending Jul 09, 2021
17309649 THERAPEUTIC USES OF GENE EDITED FIBROBLASTS TRAN, KHOA NHAT 1632 §103 Non-Final OA 127d overdue Pending Jun 11, 2021
17309207 REGENERATIVE ABSCOPAL EFFECTS RIGA, MICHAEL ANGELO 1634 §112 Non-Final OA 14d Pending May 26, 2021
17309178 TREATMENT OF CEREBRAL HYPOXIA INCLUDING STROKE, CHRONIC TRAUMATIC ENCEPHALOPATHY, AND TRAUMATIC BRAIN INJURY XU, QING 1656 §103 Non-Final OA 3d overdue Pending May 03, 2021
17251587 USE OF FIBROBLASTS AND/OR MODIFIED FIBROBLASTS FOR THREE DIMENSIONAL TISSUE PRINTING REGLAS, GILLIAN CHELSEA 1632 §103 Non-Final OA 27d Pending Dec 11, 2020
17052859 PAIN-REDUCING EFFECTS OF FIBROBLASTS AND TREATMENT OF PAIN TRAN, KHOA NHAT 1632 §103 Final Rejection 73d overdue Pending Nov 04, 2020

Managing Figene LLC's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month